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Lichen planus (LP ) and discoid lupus erythematosus (DLE) are 
separate disease entities. ~e,·ertheless, patients nith a s~alled 
"o,·erlap syndrome" have been described occasionally. The aim 
of the present study was to establish whether the LE/LP overlap 
syndrome, based on clinical and routine histological features, 
could be delineated from OLE or LP using immunohistochemical 
techniques. Formalin-fixated, paraffin-embedded skin biopsies of 
patients with OLE, LP and the overlap syndrome were compared 
regarding immunohis tochemical markers for epidermal growth 
and differentiation and extracellular matrix components. With 
the markers for extracellular matrix proteins, it was possible to 
delineate the overlap syndrome from LP. This was not possible 
for the overlap syndrome and OLE. These findi ngs might indicate 
that the LE/ LP m·erlap syndrome could be considered as LP-Iike 
OLE rather than as a distinct disease entity. Key words: 
immunohistochemistry; tenascin; laminin; heparan sulphate. 
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Lichen planus (LP) and discoid lupus erythematosus (OLE ) 
are separate disease entities. evertheless, patients with fea-
tures of both diseases, the so-called lupus erythematosus/lichen 
planus (LE/LP) overlap syndrome, have been described ( 1-5). 
No communis opinio exists as to whether the overlap syndrome 
is a distinct disease or part of a spectrum. Various investigators 
have studied the LE/LP overlap syndrome with regard to the 
clinical picture of the lesions ( 1, 2), histopathology and 
immunoOuorescence (2, 6, 7), serological differences or genetic 
background (8). 
LP and OLE are histologically distinct diseases but share 
some features as well. Both are immunologically mediated 
interface dermatoses, are inflammatory and show slight hyper-
proliferation (9-11 ). The inflammatory infiltrate expresses 
generally the same amounts of the lymphocyte activation 
marker HLA-DR (6). ln addition, using immunohistochemical 
markers for differentiation, it was shown that in OLE prema-
ture terminal differentiation is combined with normal early 
differentiation (I 0). The extent to which these features are 
deviant in patients with LP or the LE/ LP overlap syndrome 
is unknown. Histological investigations. using H&E sections 
and immunofluorescence of the LE.'LP overlap syndrome. 
have been carried out in order to delineate the syndrome from 
OLE and LP, with the combination of the two techniques 
giving the most reliable results to distinguish between DLE 
and LP (7). Nevertheless, patients with the LE/LP overlap 
syndrome could not be clearly delineated using these para-
meters (2, 3, 5, 7). 
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The aim of the present study was to establish whether the 
LE. LP overlap syndrome. based on clinical and routine histo-
logical featu res. could be delineated from OLE or LP using 
immunohistochemical techniques. To address this question, we 
chose a panel of antibodies, focusing on epidermal growth 
( Mib-1) and differentiation (keratin 10, keratin 13/ 16, involuc-
rin), together with antibodies staining extracellular matrix 
proteins ( laminin, heparan sulpha te and tenascin) ( 11- 18 ). To 
the best of our knowledge, there is no information on the 
expression of extracellular matrix proteins in OLE, LP or the 
LE/ LP overlap syndrome. 
MATERIAL AND METHODS 
Palii'IIIS 
In total. 32 patients were included in this study: 16 patients with 
cl inical and histological features of both LP and DLE. 8 patients with 
the classic features of DLE (including positive lupus band test), and 
8 patients with the classic features of LP (lupus band test negative). 
Epidemiological parameters (age, duration of iJlness. previous therap· 
ies) were recorded. The clinical picture was examined carefuJly. 
Presence of itching/painful sensations. localisation of the lesions, 
degree of atrophy, hyperpigmentation. and sensitivity to sunlight were 
recorded. The patients had not used topica l or systemic treatment for 
at least 4 weeks before the biopsy was taken. They were considered 
to have the LE LP overlap syndrome when at the same rime lesions 
were present \\ith features of both diseases. and or when histological 
features of both diseases were present in the same skin specimen. 
H istological features compatible with OLE were: follicular plugging, 
hyperkeratosis, perivascular and perifollicular patchy infiltra tes. vacu-
o lar degeneration of the basal layer, at rophy of the epidermis, and 
positive lupus band test. The diagnosis of LP was based on the 
presence of a band-like infiltrate, saw-tooth formation, Civatte bodies. 
and negative lupus band test. 
flmmmohistochemistr;· 
Biopsies were fixed in 4% paraformaldehyde and paraffin-embedded. 
and 6-(.lm sections were adhered to slides coated with 3-amino-
propyltriethoxy-silane (Sigma. St Louis. MO. USA). Sections were 
deparaffinized through xylene and rehydrated through a graded series 
of ethanols. Normal controls and blancs were included. The following 
anti sera were used for stainings on paraffin sections. To assess epi-
dermal proliferation monoclonal a ntibodies were used against a nuc-
lear antigen present in the cycling cell . Ki-67 ( Mib-1, lmmunotech 
S.A., France) and against keratin 16 and 13 (.Ks8. 12, Sigma, St Louis. 
MO, USA). Kera tin 16 is present in hyperproliferative epidermis, 
while keratin 13 has not been found in adult human skin. To 
characterise epidermal differentiation the monoclonal antibody against 
keratin 10 ( ICN Biomedicals. Zoetermcer. The Netherlands) was used 
and a monoclonal antibody against involucrin (MON-150) ( 19). 
Dermal extracellular matrix components were visualised using the 
antibody anti-tenascin (Telios. San Diego. USA). directed against the 
dermal glycoprotein tenascin. lmmunostaming of heparan sulphate 
and laminin was performed using JM-403 against the heparan 
sulphate side-chain of heparan sulphate prot co glycan (a kind gift from 
J. van den Born, Dept. of Nephrology, University Hospital Nijmegen) 
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and a polyclonal rabbit antiserum against laminin (lCN, Biomedicals, 
Zoetermeer, The Netherlands). 
An indirect peroxidase technique was used for stainings with Ks8.12, 
ant i-cytokeratin 10, anti-heparan sulphate and Mib-1. Briefly, the 
slides were pre-treated for 15 min in 0.1% trypsin/0. 1% CaCl2, pH 7.8, 
by 37oc for cytokeratin 10 and heparan sulphate. For Mib-1 two 
5-min pretreatments with 10 mM citrate buffer, using a microwave 
oven at 450 Watt , were performed. After preincubations with 20% 
normal rabbit serum the sl ides were incubated for 60 min with the 
monoclonal antibodies, and after washing with phosphate-buffered 
saline (PBS) they were incubated with rabbit-anti-mouse immunoglob-
ulin conjugated with peroxidase (RAM PO) I: 100 for 30 min. A 
solution of 3-ami»o-9-ethylcarbazole (AEC) in sodium-acetate buffer, 
pH 4.9, containing 0.01% H 20 2 , was added for 15 min after preincuba-
tion with sodium-acetate buffer, pH 4.9. 
lmrnunostainings for tenascin and laminin were performed using a 
labelled avidin-biotin peroxidase technique. The slides for anti-tenascin 
were pretreated with LO mM citrate-buffer. pH 6.0, for 30 min and 
0.1% pronase 20 min for anti-laminin. After preincubat ion with 20% 
normal goat serum the slides were incubated with goat-anti-rabbit-
biotinylated IgG (Vector Lab. Inc., Burlingame. USA) 1: 100 for 
30 min. After two washes with PBS, incubation with the avidin-biotin-
peroxidase complex (Vector Lab. Inc., Burlingame, USA) 1: 100 was 
performed. Then the slides were incubated wi th sodium-acetate buffer, 
pH 4.9, and finally stained in the AEC solution. AU slides were 
counterstained with Mayer's haematoxylin (Sigma, St Louis. MO, 
USA) and mounted in glycerol-gelatine. 
Scores 
Mib-1-stained nuclei were counted per mrn length of the section. 
Staining with the antibodies against keratin 13/ 16 and keratin 10 was 
assessed using the following scale: 0 = no staining, I = sporadic stain-
ing, 2=minimal staining. 3= moderate staining. 4 = moderate-
pronounced staining, 5 = pronounced staining, 6 = whole epidermis 
stained. MON-150 staining was expressed as percentage of stained 
epidermal cell layers per total number of cell layers. Staining for 
heparan sulphate and Ia min in was expressed as 0 = no staining present, 
1 = discontinuous staining, 2 = continuous staining. Tenascin was 
assessed as follows: O=no staining, I = discontinuous staining just 
beneath the epidermis, 2 = continuous staining just beneath the epi-
dermis, 3 = discontinuous staining just beneath the epidermis and in 
the lower parts of the dennis, 4=continuous staining just beneath the 
epidennis and in the lower parts of the dermis. 
Statistical analysis 
Data are expressed as mean± standard error of the mean. Statistical 
analysis was carried out using the Kruskal Wallis test. A p-value < 0.05 
was supposed to be statistical ly significant. 
RESULTS 
Patients 
The patient groups consisted of 8 patients with classic DLE 
( 6 female, 2 male), 8 patients with LP ( 4 female, 4 male) and 
16 patients with overlapping features ( 11 female, 5 male). 
Mean ages in years of these groups were 53.0 ± 6.4 (SEM ), 
49.3 ± 5. 7, and 49.3 ± 3.8, respectively. The mean time the 
patients had suffered from their disease was 73.5 months± 25.3 
(SEM ) in the DLE group, 25.1 ± 14.0 in the LP group, and 
45.9 ± 16.8 in the LE/ LP overlap group. Clinical features are 
illustrated in Table I. 
Immunohistochentistry 
Results of the immunohistochemical investigat ions are shown 
in Figs. 1-3. In OLE and in the LE/ LP overlap syndrome the 
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Table I. Clinical features of the three patient groups 
Clinical picture DLE LP Overlap syndrome 
(n = 8) (n=8) (n = 16) 
Location of the lesions: 
Face 7 !( 
Scalp 3 5 
Extremities 8 II 
Trunk J 9 
Mucosa 2 
Morphology: 
Atrophy 8 I 13 
Hyperpigrnentation 3 3 
Complaints: 
Itching 3 8 12 
Pain 2 6 
Provocation by sunlight 5 8 
Localisation of biopsy: 
Face 6 2 
Scalp 3 
Extremities 8 7 
Trunk 7 
numbers of Mib-1-positive cells were comparable (75.4±31.6 
(mean±SEM), and 70.7±9.9, resp.). In LP, however, the 
numbers of cycling cells were much lower ( 42.9 ± 9.1) but did 
not reach significance compared to biopsies from the LE/ LP 
overlap syndrome patients. 
Ks8. 12 binding and keratinlO were present in the supra basal 
compartment in all three groups (DLE 3.6±0.5, LP 3.6±0.5, 
LE/LP overlap syndrome 2.7 ±0.4 for Ks8.12, DLE 4.3 ±0.2, 
LP 3. 7 ± 0.2, and LE/ LP overlap syndrome 3.6 ± 0.3 for keratin 
10). No statistically significant differences between the three 
disease categories could be found. Involucrin expression was 
increased in a ll three groups, but no statistically significant 
differences could be found between DLE (67. 1 ±6.2), LP 
(65.4 ± 4.3) or the LE/ LP overlap syndrome (66.6 ±4.2). 
Heparan sulphate and laminin, mainly present in the basal 
lamina, showed clear differences in the three disease categories. 
Heparan sulphate staining was decreased in LP (0.7±0.2) 
compared to DLE (1.6 ±0.2) and the LE/ LP overlap syndrome 
( 1.6±0.0 1) . The staining pattern was discontinuous and 
patchy in LP. Delineation from the LE/ LP overlap syndrome 
was possible (p = 0.006). In addition, the difference between 
LP and DLE was statistically significant (p =O.OI ). Laminin 
staining was clearly decreased in LP (0.9 ±0.2) compared to 
the LE/ LP overlap syndrome (1.5 ± 0.2, p = 0.02). In DLE, 
laminin staining was comparable to the LE/ LP overlap syn-
drome ( 1.2 ± 0.2). 
The extracellular matrix glycoprotein tenascin was increased 
in all three disease categories. Tenascin staining was most 
notably increased in LP. Values were 2.7 ± 0.4 in DLE, 3.1 ± 0.3 
in LP, and 1.9 ± 0.3 in the overlap syndrome. The difference 
in staining pattern between LP and the LE/ LP overlap syn-
drome was stat istically significant (p = 0.03 ). 
DISCUSSION 
The first description of 4 patients with the LE/ LP overlap 
syndrome was published by Copeman et al. in 1970 (1). 
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Fig. 1. Heparan sulphate staining in LP (a) is decreased, compared 
to DLE (b) and the LE/LP overlap syndrome (c). 
Magnification x 200. 
Fig. 2. Laminin staining in LP (a), decreased compared to the LEJLP overlap syndrome (b). Magnification x 200. 
Subsequent reports postulated additional clinical and laborat-
ory parameters that could differentiate between LP, DLE and 
the LE/ LP overlap syndrome, such as clinically distinct types 
of skin lesions and a lupus-specific antigen in the sera of 
patients with LP, which should also be present in patients 
with the overlap syndrome (3). Differences in IL-2 receptors 
on T-lymphocytes were found (6), a speckled pattern of 
antinuclear antibodies was described (5), and differences in 
HLA-types were seen between DLE, LP and the overlap 
syndrome; a similar immune response in patients with different 
genotypes could lead to differences in clinical presentation of 
the disease (20). Otherwise, the hypothesis was postulated that 
these diseases form a spectrum and that there are no clear 
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criteria to distinguish between them (2). The LE/ LP overlap 
syndrome does not seem infrequent and is difficult to treat, 
although successful treatment with acitretin has been described 
(2, 5, 21 ). 
In this study, skin biopsies from patients with the classic 
forms of DLE or LP were compared to patients with clinical 
and/or histological characteristics of both diseases. Staining 
of extracellular matrix components in the dermo-epidermal 
zone and the upper dermis showed clear differences between 
the three disease categories. In LP, a discontinuous staining 
pattern of heparan sulphate was found; this is in contrast to 
the continuous staining pattern of normal skin (22). The used 
antibody, JM403, is directed against low-sulphated domains 
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Fig. 3. Tenascin staining in LP (a). clearly increased compared to the LE/ LP overlap syndrome (b). Magnification x 200. 
of heparan sulphate (23). Heparan sulphate proteoglycans are 
part of the basal lamina of various tissues. They provide 
mechanical stability, support cell-membrane-basal lamina 
interactions, bind growth factors and influence charge-
dependent transport of molecules ( 18 ). In DLE and the LE/LP 
overlap syndrome, heparan sulphate is also distributed discon-
tinuously, as indicated by the antibody JM403. From a previ-
ous study, it is known that in DLE, the core protein of 
heparan sulphate proteoglycan is unaffected and continuously 
distributed along the basal lamina. ( 10) The decreased staining 
of heparan sulphate side-chains might represent a decreased 
presence and/or an impaired function as a reservoir for growth 
factors or as a substrate for cell-membrane-basal lamina 
interactions. This might form the biological counterpart to 
impaired wound healing or atrophy of the epidermis in these 
three disease categories. 
Staining with a general antibody against laminin showed a 
decreased expression of laminin in LP. Laminin is one of the 
most important constituents of the basal lamina, providing 
resilience, adherence of keratinocytes to collagen IV in the 
basal lamina, and forms an important dermo-epidermal bridge 
(24). In the LE/LP overlap syndrome, laminin staining was 
more pronounced, compared to LP or DLE. The difference 
between the overlap syndrome and LP was statistically signi-
ficant. Decreased staining of laminin, as seen in LP, might 
represent basal lamina damage and consecutively impaired 
basal lamina function, giving lymphocytes the opportunity to 
traffic to the epidermis. 
The staining pattern of tenascin was increased profoundly 
in all three diseases, but it proved to be most prominent in 
LP. Delineation of the LEjLP overlap syndrome from LP was 
possible using this marker. The staining pattern of tenascin 
has been studied in various skin diseases. It was postulated 
that tenascin expression is increased in hyperproliferative skin 
diseases such as psoriasis, skin tumours and wound healing 
(25, 26). In addition, a correlation was seen between inflam-
mation and the expression of tenascin (27). The exact function 
of tenascin is not yet known, and it is not known whether 
tenascin is induced and/or regulated primarily by fibroblasts 
or influenced by keratinocytes or inflammatory cells. In LP. a 
prominent damage of the basal lamina is observed, which is 
indicated by decreased heparan sulphate and laminin staining. 
It is intriguing that this skin disorder, which shows the most 
pronounced loss of basal lamina components, shows the 
highest tenascin expression. This might indicate that the inter-
action of dermal and epidermal components primarily 
induces tenascin. 
Using the parameters for epidermal growth and differenti-
ation, no clear distinction could be made between the LE/LP 
overlap syndrome and DLE or LP. 
In conclusion, pronounced changes in the epidermal com-
partment as well as in the dermo-epidermal interface, as 
compared to normal skin, are seen in DLE, LP and the LE/LP 
overlap syndrome. Delineation of the LE/ LP overlap syndrome 
from LP is possible using markers for extracellular matrix 
components in the dermo-epidennal zone but is not possible 
using markers for epidermal growth and differentiation. 
Delineation of the LE/ LP overlap syndrome from DLE was 
not possible. This indicates that the LE/ LP overlap syndrome 
should be considered as LP-Iike DLE rather than as a distinct 
disease entity. Further specification of changes in extracellular 
matrix proteins in the dermo-epidermal interface can provide 
more insight into the maintenance and pathogenesis of these 
diseases. 
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